CXCR4 and neoplasm: The blockade of the C-X-C chemokine receptor type 4 (CXCR4) pathway by balixafortide played a crucial role in inhibiting metastasis and diffusion, making tumor cells sensitive to chemotherapy, and activating the immune system in the TME.